BidaskClub Upgrades Gossamer Bio (NASDAQ:GOSS) to Hold

Gossamer Bio (NASDAQ:GOSS) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Tuesday, BidAskClub reports.

Other equities analysts have also issued reports about the stock. Bank of America began coverage on shares of Gossamer Bio in a research report on Tuesday, December 3rd. They issued a “buy” rating and a $32.00 price objective on the stock. Zacks Investment Research raised shares of Gossamer Bio from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Wednesday, February 5th. ValuEngine raised shares of Gossamer Bio from a “hold” rating to a “buy” rating in a research report on Monday. Berenberg Bank assumed coverage on shares of Gossamer Bio in a research report on Wednesday, October 30th. They set a “buy” rating and a $31.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price target (down from $34.00) on shares of Gossamer Bio in a research report on Tuesday, December 17th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $27.29.

Shares of GOSS opened at $15.21 on Tuesday. The firm has a market capitalization of $1.00 billion and a PE ratio of -0.67. The company’s 50-day moving average is $14.53 and its 200-day moving average is $18.77. Gossamer Bio has a fifty-two week low of $13.12 and a fifty-two week high of $27.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 13.64 and a quick ratio of 13.64.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.10). Analysts predict that Gossamer Bio will post -3.05 earnings per share for the current fiscal year.

In other Gossamer Bio news, insider Jakob Dupont sold 1,994 shares of the stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $15.81, for a total transaction of $31,525.14. Following the sale, the insider now directly owns 1,994 shares in the company, valued at $31,525.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 23.30% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Gossamer Bio during the fourth quarter worth about $45,000. Bank of Montreal Can boosted its stake in shares of Gossamer Bio by 29.0% in the 4th quarter. Bank of Montreal Can now owns 5,962 shares of the company’s stock valued at $93,000 after purchasing an additional 1,341 shares in the last quarter. NumerixS Investment Technologies Inc acquired a new stake in shares of Gossamer Bio in the 4th quarter valued at approximately $150,000. Royal Bank of Canada boosted its stake in shares of Gossamer Bio by 39.3% in the 2nd quarter. Royal Bank of Canada now owns 6,967 shares of the company’s stock valued at $154,000 after purchasing an additional 1,967 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC acquired a new stake in shares of Gossamer Bio in the 4th quarter valued at approximately $172,000. Hedge funds and other institutional investors own 61.59% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

Featured Story: S&P 500 Index

Analyst Recommendations for Gossamer Bio (NASDAQ:GOSS)

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.